文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

急诊科高钾血症处理中50%葡萄糖推注与10%葡萄糖输注的比较评估

Assessment of dextrose 50 bolus versus dextrose 10 infusion in the management of hyperkalemia in the ED.
PubMed 文献 · Am J Emerg Med · 2019-11-16
一句话结论回顾性研究显示,接受静脉胰岛素的高钾血症患者中,D10输注预防低血糖的效果似乎不劣于D50推注,且D10组低血糖发生率无显著差异。

本研究为回顾性综述,纳入急诊科就诊、血钾>5.5 mmol/L且接受静脉胰岛素及D10输注或D50推注(3小时内)的≥18岁患者。主要终点为静脉胰岛素后24小时内低血糖(血糖≤70 mg/dL)发生率。共纳入134例患者,D50组72例,D10组62例;两组低血糖发生率无差异(D50组16例[22%] vs D10组16例[26%],p=0.77)。症状性低血糖、严重低血糖和高血糖发生率在两组间亦无显著差异。初始血糖低是发生低血糖的预测因素。作者认为,在D50注射剂短缺的背景下,D10输注可作为该患者群体的治疗策略。

要点

  • 在急诊科高钾血症接受静脉胰岛素的患者中,D10输注组低血糖(血糖≤70 mg/dL)发生率为26%(16/62),D50推注组为22%(16/72),两组无显著差异(p=0.77)。
  • 症状性低血糖发生率D50组7%(5/72) vs D10组3%(2/62),p=0.45;严重低血糖D50组7%(5/72) vs D10组2%(1/62),p=0.22;高血糖D50组47%(34/72) vs D10组37%(23/62),p=0.31。
  • 初始血糖低是发生低血糖的预测因素。
  • 作者认为,D10输注在预防低血糖方面似乎至少与D50推注同样有效,在D50注射剂短缺背景下可作为治疗策略。

适用人群与场景

  • 年龄≥18岁、急诊科就诊、血钾>5.5 mmol/L且接受静脉胰岛素及D10输注或D50推注(3小时内)的患者。

诊断标准与关键阈值

  • 高钾血症定义:血钾>5.5 mmol/L。
  • 低血糖定义:血糖≤70 mg/dL。

处置流程与药物剂量

  • D10输注或D50推注作为静脉胰岛素治疗高钾血症时的葡萄糖补充策略,具体剂量、输注速度及疗程原文未提及。

研究设计与关键结果

  • 回顾性综述纳入134例患者,D50组72例,D10组62例;主要终点24小时内低血糖发生率D50组22%(16/72) vs D10组26%(16/62),p=0.77,无显著差异。
  • 症状性低血糖D50组7%(5/72) vs D10组3%(2/62),p=0.45;严重低血糖D50组7%(5/72) vs D10组2%(1/62),p=0.22;高血糖D50组47%(34/72) vs D10组37%(23/62),p=0.31。
  • 初始血糖低是发生低血糖的预测因素。

证据类型、等级与局限

  • 证据类型:回顾性综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在D50注射剂短缺的背景下,D10输注可作为接受静脉胰岛素的高钾血症患者预防低血糖的治疗策略。
  • 初始血糖低的患者发生低血糖风险较高,需关注。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Hypoglycemia is a common adverse effect when intravenous (IV) insulin is administered for hyperkalemia. A prolonged infusion of dextrose 10% (D10) may mitigate hypoglycemia compared to dextrose 50% (D50) bolus. Our objective was to evaluate whether D10 infusion is a safe and effective alternative to D50 bolus for hypoglycemia prevention in hyperkalemic patients receiving IV insulin.

METHODS: We conducted a retrospective review of patients ≥ 18 years who presented to the emergency department (ED) with hyperkalemia (K+ > 5.5) and received IV insulin and D10 infusion or D50 bolus within 3 h. The primary endpoint was incidence of hypoglycemia, defined as blood glucose (BG) ≤ 70 mg/dL, in the 24 h following IV insulin administration for hyperkalemia.

RESULTS: A total of 134 patients were included; 72 in the D50 group and 62 in the D10 group. There was no difference in incidence of hypoglycemia between the D50 and D10 groups (16 [22%] vs. 16 [26%], p = 0.77). Symptomatic hypoglycemia, severe hypoglycemia, and hyperglycemia rates in the D50 and D10 groups were [5 (7%) vs. 2 (3%), p = 0.45], [5 (7%) vs. 1 (2%), p = 0.22], and [34 (47%) vs. 23 (37%), p = 0.31] respectively. Low initial BG was a predictor for developing hypoglycemia.

CONCLUSIONS: In our study, D10 infusions appeared to be at least as effective as D50 bolus in preventing hypoglycemia in hyperkalemic patients receiving IV insulin. In context of ongoing D50 injection shortages, D10 infusions should be a therapeutic strategy in this patient population.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Yang I, Smalley S, Ahuja T, et al. Assessment of dextrose 50 bolus versus dextrose 10 infusion in the management of hyperkalemia in the ED. Am J Emerg Med. 2019. PMID: 31837905. doi:10.1016/j.ajem.2019.09.003

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。